To further evaluate the efficacy of TRAIL–CDK9i in vivo we injected stably luciferase-expressing A549 cells (A549-luc) into the tail vein of host mice, resulting in the development of lung tumors in situ seven days after tumor cell injection, as determined by in vivo bioluminescence imaging (Fig. 3e and Supplementary Fig. 3c). This evidence concerns the gene TNFSF10 and neoplasm.